Relugolix is named as a drug or biological intervention in 2 clinical trials in our USA and China trial registers, 1 of which is recruiting. Lead sponsors include Sumitomo Pharma Switzerland GmbH (1) and Qilu Pharmaceutical Co., Ltd. (1). Registered phases: Observational and Phase 3. Conditions studied include Pregnancy Related; Pregnancy Complications; Pregnancy, High Risk.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06671548 | Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (ClinicalTrials.gov ↗) Heavy Menstrual Bleeding, Uterine Fibroids |
Phase 3 | Recruiting |
| NCT05739136 | MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy (ClinicalTrials.gov ↗) Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk |
Observational | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Pregnancy Related | 1 |
| Pregnancy Complications | 1 |
| Pregnancy, High Risk | 1 |
| Heavy Menstrual Bleeding | 1 |
| Uterine Fibroids | 1 |
| Lead sponsor | Trials |
|---|---|
| Sumitomo Pharma Switzerland GmbH | 1 |
| Qilu Pharmaceutical Co., Ltd. | 1 |
| Register | Relugolix trials |
|---|---|
| Clinical trials in USA | 1 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Relugolix works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Relugolix (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.